CHA Medical Center · Bio Group Research History CHA Medical Center · Bio Group Establishment History 1986 First Test Tube Baby Born in a Private Hospital 1986 First Birth of a Test Tube Baby through Fallopian Tube Insemination in South Korea 1987 Establishment of Sperm Bank The first case of an Asian woman being pregnant without Ovaries in the East 1988 The success of the introduction doing the first Laparoscopic Surgery in South Korea The world's first successful In Vitro cultivation of immature oocytes retrieved from discarded ovaries leading to pregnancy 1989 Awarded the Best Thesis award at the 45th Annual Meeting of the American Society for Reproductive Medicine 1991 Featured on the cover of TIME magazine, introducing the fertility research achievements of CHA Medical Center 1993 East Asia’s first successful pregnancy by direct injection of sperm into the egg 1994 Asia's first success in childbirth by direct sperm injection into the egg The first successful pregnancy in Korea through Microsurgical Tubal Reversal using laparoscopic Successful pre-implantation diagnosis of genetic diseases for the first time in Korea Introduction of CHA Medical Center Fertility Research Achievements in TIME Magazine 1996 First successful birth of a patient with Polycystic Ovary Syndrome in Asia Successful birth utilizing genetic diagnosis techniques during preimplantation Introduced CHA Medical Center Fertility Research achievements using immature oocytes in TIME Magazine 1997 Awarded Excellence award in thesis at the European Society of Reproductive Medicine 1998 Development of the world's first method for Cryopreservation of vitrified oocytes Awarded Best Thesis award and Excellence Thesis award at the 54th World Congress on Reproductive Medicine and Joint Meeting with the American Society for Reproductive Medicine simultaneously, and also received the Best Poster Award 1999 The world's first vitrified frozen egg baby pregnancy and birth success Established the world's first egg bank 2000 Awarded Best Thesis Video award from the 56th American Fertility Society 2001 New York Times has accepted CHA Fertility Center’s thesis as ‘This year’s idea’ 2002 First in the world to find genes that cause habitual miscarriage 2003 Received the Best Thesis award by American Fertility Society in the field of male fertility. 2004 Awarded Best Thesis award in Assisted Reproductive Technology field at 60th American Fertility Society 2005 First in the world to discover the use of slush nitrogen for cryopreservation CHA Fertility Center received the Best Thesis award in the field of video thesis from the American-Canada Association of Fertility Society CHA Fertility Center received the Best Presentation award at the International Symposium and Academic conferences on developmental engineering Received the Best Thesis award from American Society of Reproductive Medicine(ASRM) 2007 Developed genetically modified human embryonic stem cells, which is a new stem cell culture technique CHA Biotech succeeded to be the first in the world in inducing the differentiation of cardiovascular cells derived from embryonic stem cells 2009 Korea's first somatic cell cloning embryonic stem cell research approved First in the world to establish reverse differentiated stem cells using only protein CHA Bundang Medical Center succeeded in curing cerebral palsy patients using cord blood stem cell transplantation Received the Best Thesis award for Male Fertility from the American Society of Reproductive Medicine for successful establishment of garden stem cells 2010 CHA University secured embryonic stem cell that can be used for transplant of 25% of Koreans Successfully conceived by thawing frozen eggs of a patient with leukemia (stored in 2001) 2011 Leukemia patients successful in delivery when using defrosted egg CHA Biotech, first domestically to get clinically approved for embryonic stem cells therapy Stagart. The world's largest American Society of Reproductive Medicine establishes the Cha Kwang-Yul Stem Cell Award 2012 CHA Biotech clinically approved a senile macular degeneration of embryonic stem cell treatment CHA Vaccine Institute, initiates phase 1/2a Clinical Trial of Preventive Vaccine of 3rd generation Hepatitis B Vaccine (CVI-HBV-001) 2013 CHA Bundang Medical Center, successfully treat cerebral palsy patients with other people’s stem cell of cord bloods first in the world CHA Bundang Medical Center succeeds in the world's first Brain Transplant Cinical Trial for Parkinson's disease treatment using fetal brain stem cells CHA Biotech announced the results of clinical trials on embryonic stem cells from retinal degeneration medicine 2014 CHA Bundang Medical Center successfully performs the first clinical procedure of recurrent choriocarcinoma treatment using immune cells in Korea CHA Bundang Medical Center succeeds in the first clinical treatment for relapsed glioblastoma using immune cells for the first time in Korea CHA Biotech designated as orphan drug for the first embryonic stem cell-based Stargardt disease treatment in South Korea CHA Vaccine Institute initiates Phase 1/2a clinical trial of Therapeutic Vaccine (CVI-HBV-002) for chronic hepatitis B patients 2015 CHA Bundang Medical Center announces clinical results of Asia's first embryonic stem cell therapy (Significant vision improvement in blind patients CHA Bundang Medical Center got approval of umbilical cord-derived mesenchymal stem cell stroke treatment CHA Bundang Medical Center increased the success rate of somatic cell cloning stem cells more than three times (Cell Stem Cell thesis) CHA Biotech receives clinical approval for placenta-derived stem cell-based Alzheimer's Disease treatment CHA Vaccine Institute completes Phase 1/2a Clinical Trial of 3rd Generation Hepatitis B Vaccine (CVI-HBV-001) 2016 CHA Biotech receives clinical trial approval for Umbilical cord derived stem cell based stem cell therapy for knee cartilage defects 2017 Dr. Cha Kwangryul, Director of CHA Global Research Institute, enact a special award for Korean scientists at the American Society of Reproductive Biology CHA Vaccine Institute completed Phase 1/2a Clinical Trial of Therapeutic Vaccine (CVI-HBV-002) for Chronic Hepatitis B patients 2019 CHA Vaccine Institute initiates Phase 2b Clinical Trial of Therapeutic Vaccine (CVI-HBV-002) for Chronic Hepatitis B patients 2020 CHA Biotech receives clinical trial approval for cell therapy product CordSTEM®-DD for chronic back pain caused by degenerative lumbar disc disease CHA Biotech initiates Phase 1 Clinical Trial of Solid Tumor Immunotherapy CBT101 in Korea CHA Biotech's Solid Tumor Immunotherapy CBT101 was designated as orphan drug by the U.S. FDA 2021 CHA Bundang Medical Center develops Immunotherapy Approach for Recurrent Choriocarcinoma without Treatment Options. CHA Bundang Medical Center develops homologous NK Cell Therapy that enhances anticancer efficacy CHA Biotech completes Phase 1 Clinical Trial of Solid Tumor Immunotherapy CBT101 CHA Biotech completes Phase 1 Clinical Trial of Cell Therapy Product CordSTEM®-DD for chronic back pain caused by Degenerative Lumbar Disc Disease CMG Pharmaceutical completes Phase 1 Clinical Trial of Pan-TRK Inhibitor Targeted Anticancer New Drug CHC2014 CMG Pharmaceutical signs technology transfer agreement for Targeted Anticancer New Drug 'CHC2014' with ‘AUM Biosciences Singapore’ CHA Vaccine Institute initiates Phase 1 Clinical Trial of Non-Responder-Specific Hepatitis B Vaccine (CVI-HBV-002) CHA Vaccine institute signs technology transfer agreement for Immunomodulator 'L-pampo™' with Aston Science Co., Ltd. (2022) 2022 CHA Biotech completes administration of cell therapy product CordSTEM®-DD in Phase 2a clinical trial for chronic back pain caused by degenerative Lumbar Disc Disease CHA Vaccine Institute completes 3rd Generation Hepatitis B Vaccine Phase 1 Clinical Trial in Korea CHA Biotech initiates Phase 1 Clinical Trial of Ovarian Insufficiency Cell Therapy Product 'CordSTEM-POI' in Korea CHA Vaccine Institute receives domestic Phase 1 Approval for Varicella-Zoster Vaccine 'CVI-VZV-001' 2023 CHA Vaccine Institute administers First Subject with Varicella-Zoster Vaccine 'CVI-VZV-001' in Phase 1 Clinical Trial 1960 Opening of CHA Obstetrics and Gynecology Clinic (Founder: Cha Gyung-Seop) 1984 Opening of CHA Gangnam Medical Center (Founder: Cha Kwang-Yul) 1990 Approval for the establishment of Sungkwang Medical Foundation Opening of Sporex Diagnostic Center 1992 Opening of Women's Health Research Institute, Basic Medical Research Institute, and Genetics Research Institute 1995 Opening of CHA Bundang Medical Center 1997 Establishment of CHA University (Formerly Pocheon Jungmun Medical College) 1999 Opening of Gumi Cha Hospital 2000 Establishment of CHA Biotech Integration of Gumi Cha Hospital into a University-affiliated Hospital Opening of Daegu Cha Women's Hospital Establishment of CHA Cares 2001 Opening an International Alternative Medicine Center 2002 Establishment of a Reproductive Medicine and Infertility Genetics Research Center of CHA Medical Center 2003 Establishment of a Family Cord Blood Bank, iCord Establishment of a Public Cord Blood Bank 2004 Acquisition of Hollywood Presbyterian Medical Center in Los Angeles, USA Opening of CHA Central Research Institute 2006 Establishment of the world's largest Integrated Stem Cell Therapy Research Center at CHA Medical Center Opening of CHA Bundang Women's Medical Center 2009 Establishment of Seoul CRO (Contract Research Organization) Opening of CHA Medical Center Cell Plastic Surgery Center 2010 Establishment of the world's first High-Quality Life Center, CHAUM 2011 Opening of Global Stem Cell Clinical Trial Center in Seongnam CHAUM Establishment of CHA Vaccine Research Institute Establishment of Solidus Investment Establishment of CHA Bio F&C 2012 Establishment of CMG Pharmaceuticals 2013 Opening of CHA Bundang Medical Center Advanced Cancer Research Center Establishment of CHA Healthcare Establishment of CHA Meditech 2014 Opening of Future-oriented Research Institute at Pangyo CHA Biocomplex Opening of CHAUM medical check-up Center Samsung Branch Establishment of TCC (Total Cell Clinic) Immunotherapy Cell Clinic in Japan 2015 Opening of CHA Fertility Center Seoul Station 2018 CHA Healthcare acquires City Fertility in Australia, securing 7 infertility centers across major cities in Australia 2019 CHA Healthcare becomes the largest shareholder of SMG (Singapore Medical Group) Opening of Global Clinical Trial Center Expansion CHA Fertility Center Bundang Establishment of Matica Biotechnology in the United States 2020 Opening of CHA Ilsan Medical Center 2021 Opening of CHA Gangnam Women's Medical Center Expansion of CHA Fertility Center Daegu CHA Vaccine Research Institute to be listed on the KOSDAQ 2022 CHA Healthcare, acquired Fertility Specialists of Western Australia (FSWA) (Acquisition of 2 fertility centers in western Australia and currently holding a total of 12 fertility centers and 9 counseling offices) Matica Biotechnology completes construction of CDMO facility for global cell and gene therapy